ClinicalTrials.gg
TerminatedNCT06252285PEARLUpdated Feb 3, 2026

Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

A Phase 3 interventional study of RSVt Vaccine and Placebo in RSV Immunisation, sponsored by Sanofi Pasteur, a Sanofi Company. Terminated at 130 sites in 16 countries. Open to participants aged 6 Months to 21 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6,300
Allocation
Randomized
Ages
6 Months to 21 Months
Sex
All
01

Study summary

This study is a phase III, randomized, observer-blind, placebo-controlled, multinational, multi-center study to be conducted in approximately 6300 children 6 months to \< 22 months of age. The purpose of the study is to evaluate the efficacy, immunogenicity, and safety of Respiratory Syncytial Virus Toddler (RSVt) vaccine administered by intranasal route compared to placebo.

Eligible participants will be randomized in a 1:1 ratio to receive 2 intranasal administrations of either the RSVt vaccine or placebo.

Study duration will be 24 months for each participant. The safety follow-up will start after the first vaccination and up to the end of the study.

Read the detailed description

Study duration will be 24 months for each participant. The safety follow-up will start at inclusion and up to the end of the study.

02

Conditions studied

  • RSV Immunisation
03

In context

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 21 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: -Aged 6 months to \< 22 months on the day of inclusion (means the day of the 6-month birthday to the day before the 22-month birthday)

  • Participants who are healthy as determined by medical evaluation including medical history
  • Born at full term of pregnancy (≥ 37 weeks)

Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known systemic to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • History of medically diagnosed wheezing
  • Any acute febrile illness in the past 48 hours that according to investigator judgment is significant enough to interfere with successful inoculation on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Probable or confirmed ongoing case of viral respiratory infection (including COVID-19, influenza, rhinovirus, etc.) at the time of enrollment. A prospective participant should not be included in the study until the respiratory infection has resolved.
  • Member of a household that contains an immunocompromised individual, including, but not limited to:

    • a person who is infected
    • a person who has received chemotherapy within the 12 months prior to study enrollment
    • a person who has received (within the past 6 months) or is receiving (at the time of enrollment) immunosuppressant agents
    • a person living with a solid organ or bone marrow transplant
  • Potential close contact with other immunocompromised individual within 30 days after each vaccination as per investigator's discretion
  • Participant's biological mother's previous receipt or planned administration of an RSV vaccine during pregnancy and/or breastfeeding.
  • Receipt or planned receipt of any of the following vaccines prior to enrollment or after the first study intervention administration:

    • Any other intranasal within the 28 days prior to and after Dose 1 study administration
    • Unless given on the day of Dose 1 study administration, any other injectable live attenuated vaccines within the 28 days prior to and after. Concomitant receipt on the day of Dose 1 study administration is allowed.
  • Previous receipt of an investigational RSV vaccine or receiving any anti-RSV product (such as ribavirin or RSV immune globulin) at the time of enrollment. Previous receipt of an RSV monoclonal antibody within 6 months prior to the first study vaccine administration.
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Receipt of intranasal and intra-ocular medications within 3 days prior to study enrollment
  • Participation at the time of study enrollment or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
6,300 participants (actual)

Study arms

  • Experimental
    Group 1 RSVt Vaccine

    Participants will receive 2 intranasal administrations of RSVt vaccine

    Biological: RSVt Vaccine

  • Placebo comparator
    Group 2 Control

    Participants will receive 2 intranasal administrations of placebo

    Biological: Placebo

Interventions

  • BiologicalRSVt Vaccine

    Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal

    Also known as: 534

  • BiologicalPlacebo

    Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal

06

What researchers measure

Primary outcomes

  1. Occurrence of lower respiratory tract disease (LRTD) (during RSV Season 1) associated with any RT PCR confirmed RSV strain > 21 days post-dose 2

    Time frame: from 22 days post-dose 2 up to the start date of first occurrence of LRTD associated with any RT PCR confirmed RSV strain, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1)

Secondary outcomes

  1. Occurrence of upper respiratory tract disease (URTD) (during RSV Season 1) associated with any RT PCR confirmed RSV strain > 21 days post-dose 2

    Time frame: from 22 days post-dose 2 up to the start date of first occurrence of URTD associated with any RT PCR confirmed RSV strain, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1)

  2. Occurrence of LRTD (during RSV Season 1) associated with any RT PCR confirmed RSV strain leading to hospitalization > 21 days post-dose 2

    Time frame: from 22 days post-dose 2 up to the start date of first occurrence of LRTD associated with any RT PCR confirmed RSV strain leading to hospitalization, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1)

  3. Occurrence of severe LRTD (during RSV Season 1) associated with any RT PCR confirmed RSV strain > 21 days post-dose 2

    Time frame: from 22 days post-dose 2 up to the start date of first occurrence of severe LRTD associated with any RT PCR confirmed RSV strain, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1)

  4. Occurrence of urgent care visits, associated with an episode of LRTD over RSV Season 1, associated with any RT-PCR confirmed RSV strain > 21 days post-dose 2

    Time frame: from 22 days post-dose 2 up to the start date of first occurrence of urgent care visit associated with an episode of LRTD associated with any RT PCR confirmed RSV strain, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1)

  5. Occurrence of acute respiratory disease (ARD) (during RSV Season 1) associated with any RT-PCR confirmed RSV strain > 21 days post-dose 2

    Time frame: from 22 days post-dose 2 up to the start date of first occurrence of ARD associated with any RT PCR confirmed RSV strain, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1)

  6. Occurrence of hospitalizations, associated with an episode of ARD over RSV Season 1, associated with any RT-PCR confirmed RSV strain > 21 days post dose 2

    Time frame: from 22 days post-dose 2 up to the start date of first occurrence of hospitalizations associated with an episode of ARD associated with any RT PCR confirmed RSV strain, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1)

  7. Occurrence of urgent care visits, associated with an episode of ARD over RSV Season 1, associated with any RT-PCR confirmed RSV strain > 21 days post-dose 2

    Time frame: from 22 days post-dose 2 up to the start date of first occurrence of urgent care visit associated with an episode of ARD associated with any RT PCR confirmed RSV strain, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1

  8. Occurrence of LRTD (during RSV Season 1) associated with an RT-PCR confirmed RSV A or B strain > 21 days post-dose 2

    Time frame: from 22 days post-dose 2 up to the start date of first occurrence of LRTD associated with an RT PCR confirmed RSV A or B, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1)

  9. Occurrence of URTD (during RSV Season 1) associated with an RT-PCR confirmed RSV A or B strain > 21 days post-dose 2

    Time frame: from 22 days post-dose 2 up to the start date of first occurrence of URTD associated with an RT-PCR confirmed RSV A or B, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1)

  10. Occurrence of ARD (during RSV Season 1) associated with an RT PCR confirmed RSV A or B strain > 21 days post-dose 2

    Time frame: from 22 days post-dose 2 up to the start date of first occurrence of ARD associated with an RT-PCR confirmed RSV A or B, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1)

  11. Occurrence of LRTD (during RSV Season 1) associated with any RT PCR confirmed RSV strain > 21 days post-dose 1

    Time frame: from 22 days post-dose 1 up to the start date of first occurrence of LRTD associated with any RT-PCR confirmed RSV strain, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1)

  12. Occurrence of URTD (during RSV Season 1) associated with any RT PCR confirmed RSV strain > 21 days post-dose 1

    Time frame: from 22 days post-dose 1 up to the start date of first occurrence of URTD associated with any RT-PCR confirmed RSV strain, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1)

  13. Occurrence of ARD (during RSV Season 1) associated with any RT PCR confirmed RSV strain > 21 days post-dose 1

    Time frame: from 22 days post-dose 1 up to the start date of first occurrence of ARD associated with any RT-PCR confirmed RSV strain, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1)

  14. Occurrence of LRTD (during RSV Season 1) associated with any RT PCR confirmed RSV strain > 21 days post-dose 2, in RSV-exposed participants

    Time frame: from 22 days post-dose 2 up to the start date of first occurrence of LRTD associated with any RT-PCR confirmed RSV strain, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1

  15. Occurrence of URTD (during RSV Season 1) associated with any RT PCR confirmed RSV strain > 21 days post-dose 2, by baseline serostatus

    Time frame: from 22 days post-dose 2 up to the start date of first occurrence of URTD associated with any RT-PCR confirmed RSV strain, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1)

  16. Occurrence of ARD (during RSV Season 1) associated with any RT PCR confirmed RSV strain > 21 days post-dose 2, by baseline serostatus

    Time frame: from 22 days post-dose 2 up to the start date of first occurrence of ARD associated with any RT-PCR confirmed RSV strain, assessed up to the end of RSV season 1 (ie. up to 12 months post-dose 1)

  17. Occurrence of LRTD (during RSV Season 2), associated with any RT-PCR confirmed RSV strain

    Time frame: from 12 months post-dose 1 up to the start date of first occurrence of LRTD associated with any RT-PCR confirmed RSV strain, assessed up to the end of the study (ie. up to 24 months post-dose 1)

  18. Occurrence of URTD (during RSV Season 2), associated with any RT-PCR confirmed RSV strain

    Time frame: from 12 months post-dose 1 up to the start date of first occurrence of URTD associated with any RT-PCR confirmed RSV strain, assessed up to the end of the study (ie. up to 24 months post-dose 1)

  19. Occurrence of ARD (during RSV Season 2), associated with any RT PCR confirmed RSV strain

    Time frame: from 12 months post-dose 1 up to the start date of first occurrence of ARD associated with any RT-PCR confirmed RSV strain, assessed up to the end of the study (ie. up to 24 months post-dose 1

  20. Occurrence of LRTD (during RSV Season 2), associated with any RT PCR confirmed RSV strain, by baseline serostatus

    Time frame: from 12 months post-dose 1 up to the start date of first occurrence of LRTD associated with any RT-PCR confirmed RSV strain, assessed up to the end of the study (ie. up to 24 months post-dose 1)

  21. Occurrence of URTD (during RSV Season 2), associated with any RT PCR confirmed RSV strain, by baseline serostatus

    Time frame: from 12 months post-dose 1 up to the start date of first occurrence of URTD associated with any RT-PCR confirmed RSV strain, assessed up to the end of the study (ie. up to 24 months post-dose 1)

  22. Occurrence of ARD (during RSV Season 2), associated with any RT PCR confirmed RSV strain, by baseline serostatus

    Time frame: from 12 months post-dose 1 up to the start date of first occurrence of ARD associated with any RT-PCR confirmed RSV strain, assessed up to the end of the study (ie. up to 24 months post-dose 1)

  23. Presence of solicited administration site reactions within 21 days after each vaccination

    Number of participants experiencing solicited site reactions

    Time frame: Within 21 days after each vaccination

  24. Presence of solicited systemic reactions within 21 days after each vaccination

    Number of participants experiencing solicited systemic reactions

    Time frame: Within 21 days after each vaccination

  25. Presence of unsolicited systemic adverse events (AEs) reported in the 30 minutes after each vaccination

    Number of participants experiencing immediate unsolicited systemic AES

    Time frame: Within 30 minutes after each vaccination

  26. Presence of unsolicited AEs within 28 days after each vaccination

    Number of participants experiencing unsolicited AES

    Time frame: Within 28 days after each vaccination

  27. Presence of medically attended adverse events MAAEs throughout the study

    Number of participants experiencing MAAEs

    Time frame: Throughout the study (approximately 24 months)

  28. Presence of serious adverse events (SAEs) throughout the study

    Number of participants experiencing SAEs

    Time frame: Throughout the study (approximately 24 months)

  29. Presence of adverse events of special interest (AESIs) throughout the study

    Number of participants experiencing AESIs

    Time frame: Throughout the study (approximately 24 months)

  30. RSV A serum neutralizing antibody titers at D01

    Antibody titers are expressed as GMTs at baseline

    Time frame: Day 01

  31. RSV B serum neutralizing antibody titers at D01

    Antibody titers are expressed as GMTs at baseline

    Time frame: Day 01

  32. RSV A serum neutralizing antibody titers at 28 days post-dose 2

    Antibody titers are expressed as GMTs at post-baseline

    Time frame: 28 days post-dose 2

  33. RSV B serum neutralizing antibody titers at 28 days post-dose 2

    Antibody titers are expressed as GMTs post-baseline

    Time frame: 28 days post-dose 2

  34. RSV serum anti-F Immunoglobulin A (IgA) Electrochemiluminescence (ECL) antibody titers at D01

    Antibody titers are expressed as GMTs at baseline

    Time frame: Day 01

  35. RSV serum anti-F IgG ECL antibody titers at D01

    Antibody titers are expressed as GMTs at baseline

    Time frame: Day 01

  36. RSV serum anti-F Immunoglobulin A (IgA) ECL antibody titers at 28 days post-dose 2

    Antibody titers are expressed as GMTs post-baseline

    Time frame: 28 Days post-dose 2

  37. RSV serum anti-F IgG ECL antibody titers at 28 days post-dose 2

    Antibody titers are expressed as GMTs post-baseline

    Time frame: 28 Days post-dose 2

07

Study locations

130 sites
  • Central Research Associates - Flourish - PPDS- Site Number : 8400009
    Birmingham, Alabama 35205-1628, United States
  • Lakeview Clinical Research- Site Number : 8400024
    Guntersville, Alabama 35976, United States
  • Novak Clinical Research- Site Number : 8400069
    Tucson, Arizona 85741-2306, United States
  • Madera Family Medical Group- Site Number : 8400029
    Madera, California 93637, United States
  • Integrated Clinical Research- Site Number : 8400056
    Tarzana, California 91356, United States
  • National Institute of Clinical Research - Victorville - Hesperia Road- Site Number : 8400040
    Victorville, California 92395, United States
  • Moore Clinical Research - Brandon- Site Number : 8400065
    Brandon, Florida 33511, United States
  • Invictus Clinical Research Group- Site Number : 8400035
    Coconut Creek, Florida 33073, United States
  • Site Number : 8400031
    Doral, Florida 33122-1088, United States
  • Nona Pediatric Center- Site Number : 8400068
    Orlando, Florida 32829, United States
  • Teena Hughes Pediatrics- Site Number : 8400042
    Tampa, Florida 33613, United States
  • Morehouse School of Medicine - Atlanta- Site Number : 8400037
    Atlanta, Georgia 30310, United States
  • Emory-Children's Center- Site Number : 8400001
    Atlanta, Georgia 30322-1014, United States
  • Agile Clinical Research Trials- Site Number : 8400015
    Atlanta, Georgia 30328, United States
  • Tekton Research, LLC - 4961 Buford Hwy - Georgia - PPDS- Site Number : 8400064
    Chamblee, Georgia 30341, United States
  • Velocity Clinical Research - (Macon - Georgia) - PPDS- Site Number : 8400041
    Macon, Georgia 31210, United States
  • iResearch Savannah - CenExel - PPDS- Site Number : 8400032
    Savannah, Georgia 31405-5701, United States
  • Medical Research Partners - Ammon- Site Number : 8400059
    Ammon, Idaho 83406, United States
  • Clinical Research Prime- Site Number : 8400013
    Idaho Falls, Idaho 83404, United States
  • Leavitt Women's Healthcare- Site Number : 8400033
    Idaho Falls, Idaho 83404, United States
  • Snake River Research- Site Number : 8400046
    Idaho Falls, Idaho 83404, United States
  • Michigan Institute of Research- Site Number : 8400055
    Allen Park, Michigan 48101, United States
  • Vida Clinical Studies - Dearborn Heights- Site Number : 8400072
    Dearborn Heights, Michigan 48127, United States
  • Great Lakes Research Institute- Site Number : 8400060
    Southfield, Michigan 48075, United States
  • Clinical Research Institute - Minneapolis- Site Number : 8400011
    Minneapolis, Minnesota 55402, United States
  • Boeson Research - Great Falls- Site Number : 8400008
    Great Falls, Montana 59405, United States
  • Velocity Clinical Research - Grand Island- Site Number : 8400017
    Grand Island, Nebraska 68803, United States
  • Be Well Clinical Studies - Lincoln- Site Number : 8400058
    Lincoln, Nebraska 68516, United States
  • Velocity Clinical Research (Norfolk - Nebraska) - PPDS- Site Number : 8400038
    Norfolk, Nebraska 68701-2669, United States
  • Quality Clinical Research - Omaha - Regency Circle- Site Number : 8400016
    Omaha, Nebraska 68114, United States
  • Velocity Clinical Research - Omaha- Site Number : 8400054
    Omaha, Nebraska 68134, United States
  • Prime Global Research, Inc.- Site Number : 8400043
    The Bronx, New York 10456-2102, United States
  • Cincinnati Children's Hospital Medical Center- Site Number : 8400063
    Cincinnati, Ohio 45229, United States
  • Senders Pediatrics- Site Number : 8400006
    South Euclid, Ohio 44121, United States
  • Cyn3rgy Research- Site Number : 8400014
    Gresham, Oregon 97030, United States
  • Medical University of South Carolina - Charleston - Jonathan Lucas Street- Site Number : 8400036
    Charleston, South Carolina 29425, United States
  • Palmetto Pediatrics- Site Number : 8400012
    North Charleston, South Carolina 29406, United States
  • Parkside Pediatrics - Simpsonville- Site Number : 8400071
    Simpsonville, South Carolina 29681, United States
  • Clinical Research Associates Inc- Site Number : 8400005
    Nashville, Tennessee 37203-2066, United States
  • Tekton Research, LLC - Beaumont - PPDS- Site Number : 8400061
    Beaumont, Texas 77706-3061, United States
  • South Texas Urgent Care - Del Rio- Site Number : 8400062
    Del Rio, Texas 78840-3927, United States
  • Ventavia Research Group - Fort Worth- Site Number : 8400022
    Fort Worth, Texas 76104, United States
  • Private Practice - Dr. Chinyere N. Awa- Site Number : 8400066
    Houston, Texas 77057, United States
  • DM Clinical Research - CyFair Clinical Research Center- Site Number : 8400044
    Houston, Texas 77065, United States
  • Maximos Ob/Gyn- Site Number : 8400023
    League City, Texas 77573, United States
  • Pediatric Center - Richmond- Site Number : 8400019
    Richmond, Texas 77469, United States
  • Tekton Research - FM78- Site Number : 8400067
    San Antonio, Texas 78244, United States
  • Alliance for Multispecialty Research - Layton - North Robins Drive- Site Number : 8400030
    Layton, Utah 84041, United States
  • Wee Care Pediatrics - Roy- Site Number : 8400002
    Roy, Utah 84067, United States
  • Wee Care Pediatrics - Syracuse- Site Number : 8400004
    Syracuse, Utah 84075, United States
  • Investigational Site Number : 0320007
    Buenos Aires, Buenos Aires F.D. C1425, Argentina
  • Investigational Site Number : 0320003
    Río Cuarto, Córdoba Province X5800, Argentina
  • Investigational Site Number : 0320005
    Rosario, Santa Fe Province S2013DTC, Argentina
  • Investigational Site Number : 0320004
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Investigational Site Number : 0320002
    SAN Miguel de Tucumã¡n, Tucumán Province T4000, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1426, Argentina
  • Investigational Site Number : 0320006
    Buenos Aires, 1426, Argentina
  • Obras Sociais Irmã Dulce - Patamares- Site Number : 0760009
    Salvador, Estado de Bahia 41680-020, Brazil
  • Freire Pesquisa Clínica - Belo Horizonte - Rua Piauí- Site Number : 0760001
    Belo Horizonte, Minas Gerais 30150-320, Brazil
  • Hospital de Clinicas de Porto Alegre- Site Number : 0760005
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Hospital Ernesto Dornelles- Site Number : 0760007
    Porto Alegre, Rio Grande do Sul 90160-093, Brazil
  • Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP - PPDS- Site Number : 0760010
    Ribeirão Preto, São Paulo 14015-010, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto- Site Number : 0760006
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Escola Paulista De Medicina- Site Number : 0760002
    Vila Clementino, São Paulo 04023-062, Brazil
  • Centro Paulista de Investigaçăo Clínica - CEPIC- Site Number : 0760004
    São Paulo, 04265-000, Brazil
  • Investigational Site Number : 1520004
    Santiago, Reg Metropolitana de Santiago 8331143, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 8380418, Chile
  • Investigational Site Number : 1520005
    Port Montt, 5480000, Chile
  • Investigational Site Number : 1560009
    Jiangsu, 221699, China
  • Investigational Site Number : 1700004
    Acacías, 507001, Colombia
  • Investigational Site Number : 1700002
    Chía, 250001, Colombia
  • Investigational Site Number : 1700003
    Girardot, 252431, Colombia
  • Investigational Site Number : 2460003
    Espoo, 02230, Finland
  • Investigational Site Number : 2460005
    Helsinki, 00100, Finland
  • Investigational Site Number : 2460008
    Jarvenpaa, 04400, Finland
  • Investigational Site Number : 2460004
    Kokkola, 67100, Finland
  • Investigational Site Number : 2460002
    Oulu, 90220, Finland
  • Investigational Site Number : 2460006
    Seinäjoki, 60100, Finland
  • Investigational Site Number : 2460009
    Tampere, 33100, Finland
  • Investigational Site Number : 2460001
    Turku, 20520, Finland
  • Investigational Site Number : 3920008
    Lizuka-shi, Fukuoka 820-0040, Japan
  • Investigational Site Number : 3920011
    Sapporo, Hokkaido 063-0841, Japan
  • Investigational Site Number : 3920007
    Kawagoe, Saitama 350-0001, Japan
  • Investigational Site Number : 3920010
    Shizuoka-Shi Aoi-Ku, Shizuoka 420-0005, Japan
  • Investigational Site Number : 3920006
    Edogawa-Ku, Tokyo 133-0056, Japan
  • Investigational Site Number : 3920001
    Fukui, 910-0833, Japan
  • Investigational Site Number : 3920002
    Fukui-shi, 910-0808, Japan
  • Investigational Site Number : 3920004
    Fukuoka, 813-0036, Japan
  • Investigational Site Number : 3920003
    Kagoshima, 890-0034, Japan
  • Investigational Site Number : 3920005
    Kasuga-Shi, 816-0801, Japan
  • Investigational Site Number : 3920009
    Osaka, 556-0005, Japan
  • Investigational Site Number : 4040007
    Butere, 50101, Kenya
  • Investigational Site Number : 4040002
    Kisumu, 40100, Kenya
  • Investigational Site Number : 4040003
    Kisumu, 40100, Kenya
  • Investigational Site Number : 4040001
    Nairobi, 00202, Kenya
  • Investigational Site Number : 4040006
    Nairobi, KENYA, Kenya
  • Investigational Site Number : 4840008
    Monterrey, Nuevo León 64060, Mexico
  • Investigational Site Number : 4840007
    Mexico City, 14090, Mexico
  • Investigational Site Number : 4840004
    Veracruz, 91900, Mexico
  • Investigational Site Number : 5240003
    Dhulikhel N.p, Bagmati 45210, Nepal

Showing the first 100 of 130 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Dec 2025, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2024
First posted
Feb 9, 2024
StartActual
Feb 6, 2024
Primary completionActual
Dec 4, 2025
CompletionActual
Dec 4, 2025
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06252285
Responsible party
Sponsor
First posted
Feb 9, 2024
Start date
Feb 6, 2024
Primary completion
Dec 4, 2025
Completion
Dec 4, 2025
Last update
Feb 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion